Medscape February 3, 2025
A majority of people with overweight or obesity prescribed glucagon-like peptide 1 receptor agonists (GLP-1 RAs) discontinue them within 1 year, with higher quit rates among those without type 2 diabetes (T2D), new research suggested.
The data, from electronic health records of more than 125,000 adults who initiated GLP-1 RA treatment in the United States, showed that just over half stopped using GLP-1 RAs at 1 year. More than two thirds of those without T2D did so compared with just under half of those with T2D.
In addition, people without T2D were also less likely to reinitiate GLP-1 RAs within a year after stopping them. Weight loss, income, and adverse events were significantly associated with discontinuation, while weight regains predicted...
Today's Sponsors
Today's Sponsor